Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
Bibliographic record
Abstract
Canakinumab (CAN) is indicated for the treatment of cryopyrin-associated periodic syndrome (CAPS) in patients ≥2 years of age.[ 1 ] However, patients may require treatment in infancy where CAN has not yet been studied. IL-1 inhibition has not affected antibody production after vaccination in healthy volunteers[ 2 ], but no data in patients receiving standard childhood vaccines are available. To evaluate the efficacy and safety of CAN, including post-vaccination antibody production, in children with CAPS <4 years of age. CAN-naïve patients aged 28 days to 4 years with CAPS received open-label CAN dosed 2-12 mg/kg every 4 or 8 weeks for 56 weeks. Efficacy was evaluated by complete response (clinical response and normal C-reactive protein [CRP]) and subsequent relapse. Safety was assessed by adverse event (AE) reporting and vaccination response evaluated by post-vaccine antibody titers measured at 28 and 57 days post vaccination. Vaccines evaluated included DTP; H. Flu; N. Men.; influenza; Hep B; and Strep. Pneum. Of 17 patients enrolled, 6 were less than 24 months old (44 days-5 months). The phenotypic distribution was: FCAS (n=1), MWS (n=12), and NOMID (n=4). All 17 patients achieved a clinical response and 16 achieved a complete response. Seven patients required dose escalation to achieve and/or maintain their responses. The patient who did not achieve a complete response was a 1 year old with persistently elevated CRP. Of the 16 patients with a complete response, 4 (2 with MWS and 2 with NOMID) subsequently relapsed, but all regained complete response; 2 (1 MWS; 1 NOMID) with and 2 (1 MWS; 1 NOMID) without dose escalation. No CAPS flares were reported with vaccination and a rise in post-vaccination antibody titers was observed for all vaccines evaluated. The most common type of AE reported was an infection, typically involving the upper respiratory tract. Four patients experienced a serious AE (SAE), with no SAE occurring more than once. No patient discontinued due to an AE. Canakinumab is an effective treatment for patients with CAPS aged as young as 44 days old. Canakinumab appears to have no effect on the ability to produce antibodies against standard childhood non-live vaccines. The safety profile of canakinumab was acceptable and similar to that observed for older patients.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".